Cell & Gene Therapy Supply Chains: Precision At Every Step

In traditional clinical trials, supply disruptions can create delays. In cell and gene therapy studies, they can have far greater consequences. Because each treatment is manufactured from an individual patient's own cells, every enrolled participant effectively requires a unique, end-to-end supply chain. From cell collection and manufacturing scheduling to cold-chain logistics, site readiness, and final infusion, every step must occur in the correct sequence and within strict timelines.
​
The challenge lies not only in the complexity of the process, but also in coordinating multiple stakeholders who often operate across different systems and workflows. A scheduling error, communication breakdown, or chain-of-identity issue can jeopardize a patient's opportunity to receive treatment.

Purpose-built RTSM platforms are helping sponsors address these challenges by connecting manufacturing scheduling, patient eligibility, logistics coordination, and chain-of-identity tracking within a unified workflow. Discover how specialized approaches to trial supply management can help reduce operational risk, improve coordination, and support the growing demands of cell and gene therapy research.